Last reviewed · How we verify
Consolidation With Campath-1H After FMC Induction in Patients With T-cell Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as fludarabine, cyclophosphamide, and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others can find cancer cells and help kill them or carry cancer-killing substances to them. Combination chemotherapy followed by alemtuzumab may be effective in treating chronic lymphocytic leukemia and prolymphocytic leukemia. PURPOSE: This phase II trial is studying how well giving combination chemotherapy followed by alemtuzumab works in treating patients with T-cell chronic lymphocytic leukemia or prolymphocytic leukemia.
Details
| Lead sponsor | German CLL Study Group |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 17 |
| Start date | 2002-09 |
| Completion | 2009-12 |
Conditions
- Prolymphocytic Leukemia
Interventions
- alemtuzumab
- cyclophosphamide
- fludarabine phosphate
- mitoxantrone hydrochloride
Primary outcomes
- Adverse effects at 2 months after treatment
- Remission rate at 2 months after treatment
Countries
Austria, Germany